Congress:
ECR25
Poster Number:
C-10265
Type:
Poster: EPOS Radiologist (scientific)
Authorblock:
F. Herr, M. J. Antons, L. Blume, J. Stueckl, H. Hirner-Eppeneder, J. Ricke, M. Heimer, D-A. Clevert, C. C. Cyran; München/DE
Disclosures:
Felix Herr:
Nothing to disclose
Melissa J. Antons:
Nothing to disclose
Larissa Blume:
Nothing to disclose
Jennifer Stueckl:
Nothing to disclose
Heidrun Hirner-Eppeneder:
Nothing to disclose
Jens Ricke:
Nothing to disclose
Maurice Heimer:
Nothing to disclose
Dirk-André Clevert:
Nothing to disclose
Clemens C. Cyran:
Nothing to disclose
Keywords:
Molecular imaging, Oncology, Ultrasound physics, MR-Functional imaging, PET-CT, Ultrasound, Experimental investigations, Molecular imaging, Radionuclide therapy, Cancer, Image guided radiotherapy, Molecular, genomics and proteomics
Murine melanoma allografts (B16-F10) were implanted subcutaneously in n = 10 therapy and n = 10 control female C57BL/6 mice. Baseline CEUS with VEGFR2-targeted MB (BR55) was performed on day 7 and follow-up on day 12. The therapy group received 3 intraperitoneal injections on days 7, 9 and 11, the control group received a placebo. CEUS assessed tumour perfusion during an early vascular phase (wash-in area under the curve = WiAUC) and VEGFR2-specific binding during a late molecular phase (signal intensity at 8 minutes (SI8min) and 10 minutes (SI10min)). For pathophysiological validation immunohistochemical assessments were performed.